Full-Time
Executive Production
Sanofi
10,001+ employees
Global pharma company; vaccines and R&D
No salary listed
Verna, Goa, India
In Person
Bachelor's
 Operations & Logistics (1) |
|---|
Get referred to Sanofi
See people who can refer or advise you
- The candidate must have 1 to 5 years of experience.
- The candidate must have experience in tablet and capsule manufacturing.
- The candidate must have graduate or postgraduate education.
- The candidate must know English and be able to write and communicate in English.
- The candidate must have proficiency in Microsoft Word, Microsoft Excel, SAP, and Microsoft PowerPoint.
- The candidate must have knowledge of Good Manufacturing Practice and health, safety, and environmental systems.
- Allocate scheduled activities to operators during the shift according to the production plan.
- Allocate manpower and necessary accessories to activities as needed to complete the work.
- Maintain discipline among manpower resources and comply with certified standing orders.
- Complete scheduled output within standard time and prioritize activities to provide continuous feed to the next process.
- Communicate with shift supervisors and subordinates about activities completed during the shift.
- Share product-critical manufacturing information during shift handovers through the status board and direct communication.
- Ensure operator and manpower activities comply with effective standard operating procedures and specified batch manufacturing record parameters.
- Ensure in-process tests are performed at the required frequency and comply with acceptance criteria.
- Identify, troubleshoot, and report quality defects and online process-test failures, and perform stringent acceptable quality limit checks according to batch manufacturing records and standard operating procedures.
- Compile, check, and submit completed batch manufacturing records to Quality Assurance.
- Ensure products are manufactured and stored as required, implement the quality system, maintain Good Documentation Practice for batch manufacturing records, logbooks, and log cards, and follow data-integrity attributes.
- Create purchase orders and determine materials according to first-in, first-out requirements in SAP.
- Prepare goods-issue slips for completed batches in SAP and record consumption of tertiary packaging materials used in manufacturing.
- Perform bulk posting of completed batches in SAP as required.
- Carry out technically complete processing for finished process orders online.
- Receive the production plan, execute it, and coordinate with cross-functional departments to communicate requirements for completing the plan.
- Monitor daily activities and plan changeovers to maximize scheduled production time for dispensing, granulation, mixing, compression, and coating.
- Maintain adequate work-in-process levels and documentation for products manufactured at the Goa site.
- Improve processes, cycle time, yields, and capacity utilization to improve cost of goods manufactured.
- Develop action plans with team members to improve process performance, quality, and productivity.
- Update overall equipment effectiveness and equipment details in designated records and assist Lean Management with accurate data collection for process excellence.
- Train new joiners on the job before assigning them work.
- Train and guide subordinates in implementing Good Manufacturing Practice and health, safety, and environmental systems and developing people.
- Provide training and guidance to subordinates for new product transfer strategy and documentation processes, including validation protocols and batch production records.
- Coordinate product revalidation, process validation, and study batches; prepare protocols and reports; validate manufacturing activities; and ensure release according to plan.
- Implement health, safety, and environmental systems, maintain safe working conditions, and support continuous improvement.
- Initiate departmental safety committee meetings and obtain associate suggestions to improve working conditions and reduce risk.
- Review implemented procedures periodically and evaluate them.
- Train personnel on safety and their jobs to help prevent lost-time and injury-without-lost-time incidents.
- Conduct daily training in the +QDCI meeting and address unsafe conditions.
- Complete and implement manufacturing compliance activities, including deviation investigations, out-of-specification and out-of-trend investigations, corrective and preventive action implementation, regulatory-audit handling, and related corrective and preventive action implementation.
- Assist with qualification of new or modified equipment by preparing user requirement specifications, performance qualification protocols, and reports.
- Ensure equipment qualification meets Good Manufacturing Practice standards and user requirements with supporting departments.
Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Get referred to Sanofi
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales rose 17.8%; Dupixent topped €5.2 billion for the quarter.
- July 30 upgraded 2026 guidance to around 10% sales growth, with higher EPS.
- August 4 MenQuadfi infant approval widens vaccine reach; Nexviazyme's June phase 3 readout strengthens pipeline.
What critics are saying
- Dupixent faces tougher H2 2026 comparisons, threatening growth after the €5.2 billion quarter.
- Cenrifki carries liver injury risk; strict monitoring can slow adoption and invite liability.
- Dupixent concentration and Regeneron's November 2024 lawsuit threaten Sanofi's core growth engine.
What makes Sanofi unique
- Dupixent and partnered launch engine generate repeatable immunology cash flows across geographies.
- Sanofi converted 2026 approvals for Sarclisa Escena, Wayrilz, and Cenrifki into launches.
- Paulo Fontoura's September 1 R&D mandate centralizes translational science and regulatory execution.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Parental Leave
Company News
Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD
InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.
Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.
The US Food and Drug Administration has approved Sanofi's subcutaneous Sarclisa Escena for treating multiple myeloma, making it the first anticancer treatment administered through an on-body injector. The therapy uses Enable Injections' CirCLIQ device, which delivers the drug automatically with a retractable 30g needle. The approval was supported by the IRAKLIA phase 3 study, which demonstrated that Sarclisa Escena delivered via the on-body injector provided similar efficacy and safety compared to intravenous infusion, with significantly shorter treatment time and fewer infusion-related reactions. The study showed a 71.1% objective response rate in patients with relapsed or refractory multiple myeloma. More than 70,000 patients worldwide have been treated with Sarclisa-based regimens. The on-body injector aims to reduce physical burden on healthcare providers whilst offering patients greater convenience during treatment.
Sanofi has appointed Paulo Fontoura as Executive Vice President and Global Head of Research & Development Pharma, effective 1 September. Based in Paris, Fontoura will oversee the company's innovation engine, spanning research, translational medicine, clinical development, and regulatory affairs. He succeeds Dr Houman Ashrafian, who is leaving to pursue new opportunities. Fontoura brings over 25 years of experience across academic medicine, translational science, and pharmaceutical innovation. The appointment comes as Sanofi drives an R&D transformation whilst progressing its pipeline across multiple therapeutic areas. Separately, MacroGenics confirmed it will receive $24.5 million in regulatory milestone payments from Sanofi following FDA accelerated approval of TZIELD to delay decline in endogenous insulin production in children. Sanofi is a global biopharmaceutical company focusing on immunology, rare diseases, and oncology.